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ABSTRACT 
Introduction: In complex treatment of ch ronic obstructive pulmonary disease (COPD) combined with ischemic heart disease (IHD) more and more attention is drawn to 
pleiotropic effect of statins. 
The aim of our researches became determining the effectivityof utilization of rosuvastatin (CRESTOR®, IPR PHARMACEUTICALS, Inc.) in complex treatment ofCOPD combined with IHD. 
Materials and methods: Basing on pulmonology department of Poltava regional clinical hospital, 30 patients with COPD combined with IHD have been examined (stable 
effort angina FC II) aged from 51 to 67 y.o. (average age was 57,03 ± 3,51 ). The patients were divided into two age compatible groups. Patients of the main group (n = 15) 
underwent regular COPD and IHD treatment, addind 20 mg of rosuvastatin per night. The observed group (n"" 15) didn't receive rosuvastatin. 
The examination of patients was held before and half year of treatment, included the estimation of respiratory symptoms of the disease, the degree of intensity of dyspnea 
(Medical Research Council Dyspnea Scale). The tolerance to physical exercise was studied with 6 minute walking test. The cholesterine level, HDL, LDL, function ofventilation 
have been tested as well. The average frequency of aggravations during the year was estimated through retrospective examination of anamnesis. 
Results: After the treatment the improvement of clinical state has been noticed at both groups due to decrease of intensity of respiratory symptoms of the disease, such as 
cough, amount of expectoration, dyspnea and also increase of tolerance to physical exercise and improvement of laboratory-instrumental indexes. Though the patients of the 
main group were noticed to have significantly less amount of expectoration and cough. The distance covered in 6 minutes was positively longer (p < 0,05). 
It has to be noted that the patients of the main group had positive decrease of wheezing after treatment, due to increase of FEVl, GI (p <0,05). Also, the positive decrease of 
general cholesterine in blood took place, along With triglyceride and LDL, and increase ofHDL (p < 0,01 ). The retrospective studying of the anamnesis revealed that the frequency 
of arrogations during the year was 1-2 times a year (1,6 ± 0,48). 
Conclusions: Including rosuvastatin into the treatment scheme allows to decrease and stabilize the main clinical symptoms of this constellation of diseases, improving the 
quality of life, reduce the frequency of exacerbations. 
~~ KEY WORDS: chronic obstructive pulmonary disease, ischemic heart disease, rosuvastatin, pleiotropic effect. 
INTRODUCTION 
Today doctors are increasingly facing the so-called co-
morbid course of chronic obstructive pulmonary disease 
(COPD) and ischemic heart disease (IHD), which is 
accompanied with the syndrome of mutual burdening 
and development of the "vicious circle': which leads to 
deterioration of COPD and has a negative impact on the 
effectiveness of basic treatment. Taking into account these 
circumstances, the considerable attention is paid to treat-
ment of co-morbidities in the international consensuses 
and protocol of patients with COPD [5]. 
Most confirmed hypotheses consist in the fact that in such 
an association diseases are connected with common risk 
factors (active or passive smoking, adverse environmental 
conditions, respiratory tract infections) which cause chronic 
Wiad Lek 2017, 70, 2, cz.11, 303-305 
systemic inflammation by acting on vascular endothelial 
cells, airway epithelium, lung parenchyma [6). 
The use of basic medications for the treatment of 
COPD, such as inhaled corticosteroids, has a pronounced 
anti-inflammatory effect on both the local and systemic 
levels, and it does not ensure the complete elimination of 
inflammation [3, 7]. 
Taking into account the common risk factors and pathoge-
netic mechanisms in development of both diseases, increas-
ing attention has been paid to the use of statins in treatment 
of COPD. This group of medications except the main one -
of lipid-lowering action, has pleiotropic (anti-inflammatory, 
immunomodulatory, and antioxidant) effects, influencing 
not only the condition of the vascular wall, but also the 
diseases of respiratory system [2, 4). Under the influence 
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Table I. Clinical and instrumental indicators in patients with COPD of B group in the combination with lHD, FC ll 
"> . ~i-. _,. . . ,;;· the I group (mai~) . - - ·:{ ~?!~groupJL(cohJro_lL~- ·-. . 
{n_• _ dicati tt ~:. . >=~ After 6 months of. ., .. . , · ·Att~·r'6months"of ;"'" ·., ;.~t: B.eforet~~~tment -•c ,,Jreatment Beforf tr~at{i5_~nt . . -treatment·~~,- ·::::; 
Cough {scores) 2.2±0.13 1.75±0.05*# 2.3±0.13 1.9±0.06* 
Sputum (scores) 2.32±0.17 1.61 ±0.06*# 2.4±0.16 1.78±0.07* 
Breathlessness (scores) 2.33±0.12 1.73±0.10* 2.27±0.11 1.82±0.1 0* 
6-minute test {m) 411.47±20.57 468.17±19.35* 409.20±20.46 453.47±18.58 
56.23±3.01 66.57±3.27* 55.51±2.98 62.8±3.02 
GI 62.7±3.76 74.1 ±3.61 * 63.33±3.8 70.26±3.51 
* (p < 0.05 - p <0. 001) significant difference of indicators in the dynamics of treatment; 
# (p < 0.05) significant difference of indicators between the groups after treatment. 
"table l\. Lipid prnfil!! \ndlcato(s \n patients w\tt\ COPO of B grnup ln tt\e combination witt\ \HO, fC ll 
the I group (main) QfOUP II (control) 
_: --.. ~ . • ~- · · · After 6.months:of ·-: -~: · . .. . -·. · i i~},;-.:• · -
.·BeJor_e treatm,12nt< _-:r .,,,.. · _ t .. - t t ··. ·.·  __ _-; -;._ ··; Before treatr:i:ie,1;1t;~ · · 
Aft~r 6 rnonth;·of/;·-
.. treatm~!J!\ · "i;~i;t~ ·: . . ·---::~.-" . . - -- rea men_ . . --··. -:··,,· . • .. ... ,·--'!er--. . 
Cholesterol 5.88±0.35 4.20±0.25*# 5.77±0.35 5.75±0.35 
Triacylglycerol 2.17±0.11 1.68±0.08*# 2.14±0.11 2.16±0.08 
LDL 3.38±0.20 2.43±0.15*# 3.25±0.20 3.23±0.19 
HDL 0.95±0.05 1.16±0.06* 1.06±0.05 1.05±0.05 
*(p<0.01 - p<0.001) significant difference of indicators in the dynamics of treatment; 
#(p<0.001) significant difference of indicators between the groups after treatment. 
of statins, a decrease in the level of systemic inflammation 
markers and C-reactive protein (CRP) occurs, by means of 
reducing the production of interleukin-6 [ l, 8). 
The results of randomized multicenter studies demon-
strated that statin therapy in high doses reduces the risk of 
mortality in patients with COPD, decreases exacerbations 
and slows the processes of emphysema development [ 9, 10]. 
Statins have pleiotropic effects, most of which, in our opin-
ion, with this conste1lation of diseases, is anti-inflammatory. 
Thus, the use of statins in treatment of COPD combined 
with ischemic heart disease requires further study. 
THE AIM 
The aim of the research is to investigate the clinical efficacy 
of the use of rosuvastatin (CRESTOR~, IPR PHARMA-
CEUTICALS, Inc.) in treatment of COPD combined with 
ischemic heart disease. 
MATERIALS AND METHODS 
We examined 30 patients with COPD of B group combined 
with ischemic heart disease (stable exertional angina ofFC II) 
aged from 51 to 67 ( average age was 5 7. 03 ±3 .51) who were hos-
pitalized in the Pulmonology Department of Poltava regional 
clinical hospital named after M. V. Sklifosovsky. The study was 
carried out at the Research Institute for Genetic and immuno-
logical bases of pathology and pharmacogenetics higher state 
educational institution of Ukraine "Ukrainian Medical Dental 
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Academy" (HSEIU "UMCA'.'). The average duration ofCOPD 
in examined patients was between 10 and 15 years. 
The diagnosis of COPD was established in accordance 
with the order of the Ministry of Public Health of Ukraine 
No 555 as of06.27.2013 and the provisions set forth in the 
document GOLD (Global Initiative for Chronic Obstruc-
tive Lung Disease). IHD diagnosis was verified on the basis 
of clinical picture, medical history, ECG, and a six-minute 
walk test (SMWT). 
According to the aim of the study, all patients were di-
vided into two groups. Patients were selected based on the 
"case-control" method, so that the groups were comparable 
in terms of age, COPD group, FC of stable angina. 
Patients of the main groups (n ::: 15) received COPD 
protocol therapy, namely 25 µg of serevent by two inha-
lations twice a day; if necessary, 0.4 g of aerofillin twice a 
day, 0.3 g of ambroxol twice a day. The protocol treatment 
of lHD included isosorbide-dinitrate at a dose of 20-40 
mg/ day, cardiomagnil at a dose of 75 mg / day, 10 mg of 
rosuvastatin. Patients of the control group (n = 15) did not 
take rosuvastatin. 
Patients were examined before and 12 days after treatment, 
therapy included the assessment of respiratory symptoms . 
on a scale from O (no symptoms) to 3 (considerably severe 
symptoms). The degree of dyspnea was assessed using a 
modified scale of dyspnea (shortness ofbreath), MRC (Med-
ical Research Counsil Dyspnoea Scale). Exercise tolerance 
was studied by a six-minute walk test (SMWT), which was 
conducted according to standard procedures. 
DETERMINE THE EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE 
The distance that a patient covers over the period 6 
minutes was taken into account. The level of cholesterol, 
LDL, HDL was determined. The respiratory function was 
defined: FEV l (forced expiratory volume in the 1st sec-
ond), FEVl / FVC - Gaensler index (GI), Tiffeneau index 
modification FEVI / VC. 
The average frequency of exacerbations during the pre-
vious year has been evaluated by a retrospective study of 
medical history. 
Statistical analysis was performed using Excel 7.0 editor. 
The results are given in the tables as the arithmetic average 
± standard deviation (M ± m). In order to evaluate the 
differences in performance as compared with the original 
data, Student's t-test was used. A significant difference was 
considered with the error probability p <0.05. 
RESULTS AND DISCUSSION 
After the treatmen t of patients in both groups, the im-
provement in clinical status was detected due to decreased 
severity of respiratory symptoms: cough, sputum, dyspnea, 
as well as increased exercise tolerance and improved labo-
ratory and instrumental performance. 
It was noted that regression of the respiratory symptoms 
in the main group of patients was more manifested in the 
comparative analysis of clinical symptoms between the 
groups. Thus, the patients of the main group had statistical-
ly significant decrease in the intensity of cough and quantity 
of sputum than patients in the control group (p < 0.05). 
Furthermore, the pattern has been observed in the anal-
ysis of tolerance to physical activity between these groups 
of patients. After treatment patients had the increased 
tolerance to physical activity, but the patients of group II 
did not have a substantial nature of this condition, whereas 
the patients of the main group had significantly higher 
index (p < 0.05). 
It should be noted that in patients of the main group after 
6 months of treatment there was significant reduction of 
wheezing by means of increased FEV 1 and GI (p <0.05). 
Having analyzed the lipid levels in patients from the 
main and control groups before and after treatment, the 
significant difference was observed. Thus, after treatment 
in patients of the main group, as one can see from Table 
2, there was a significant reduction in blood levels of 
total cholesterol, triglycerides, LDL and increase in HDL 
(p < 0.01). 
When assigning means rosuvastatin were observed se-
rious adverse eve·nts, which demanded its cancellation or 
destination other medicines to reduce side effects. 
The retrospective study of the case history ( 1.6 ± 0.48) 
revealed that the frequency of exacerbations in the past 
year was observed from 1 to 2 times per year. 
CONCLUSIONS 
1. Inclusion of rosuvastatin in the comprehensive treatment 
of patients with COPD in combination with IHD can 
reduce and stabilize the main clinical manifestation of this 
constellation of diseases through its pleiotropic action, most 
of which is anti-inflammatory. 
2. When assigning means rosuvastatin were observed serious 
adverse events, which demanded its cancellation or desti-
nation other medicines to reduce side effects. 
3. The frequency of exacerbations of COPD in patients with 
cardiovascular pathology with the use of statins is significan-
tly reduced; thereby the quality of patients life is improved. 
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